| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0732-8893(02)00525-4 |
| P698 | PubMed publication ID | 12663162 |
| P50 | author | Ana Espinel-Ingroff | Q108430078 |
| Javier Peman | Q43166205 | ||
| Guillermo Quindós Andrés | Q43182008 | ||
| P2093 | author name string | Emilia Cantón | |
| Miguel Gobernado | |||
| Guillermo Quindós | |||
| Angel Viudes | |||
| P2860 | cites work | In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi | Q28355507 |
| In vitro activities of terbinafine against Aspergillus species in comparison with those of itraconazole and amphotericin B | Q28365213 | ||
| Bloodstream infections due to Candida species: SENTRY antimicrobial surveillance program in North America and Latin America, 1997-1998. | Q30453663 | ||
| Do in vitro susceptibility data predict the microbiologic response to amphotericin B? Results of a prospective study of patients with Candida fungemia. | Q32122087 | ||
| Comparison of in vitro antifungal activities of free and liposome-encapsulated nystatin with those of four amphotericin B formulations | Q33693450 | ||
| Quality control limits for broth microdilution susceptibility tests of ten antifungal agents | Q33969748 | ||
| Candida parapsilosis: epidemiology, pathogenicity, clinical manifestations, and antimicrobial susceptibility | Q35249261 | ||
| Trichosporon beigelii, an emerging pathogen resistant to amphotericin B | Q37186512 | ||
| Effects of amphotericin B and fluconazole on the extracellular and intracellular growth of Candida albicans | Q40087970 | ||
| In vitro susceptibility of Candida dubliniensis to current and new antifungal agents | Q43651355 | ||
| In-vitro testing of susceptibility to amphotericin B is a reliable predictor of clinical outcome in invasive aspergillosis. | Q51193344 | ||
| Amphotericin B tolerance: a characteristic of Candida parapsilosis not shared by other Candida species. | Q54504401 | ||
| Timed-kill curves for Cryptococcus neoformans isolated from patients with AIDS | Q73991732 | ||
| P433 | issue | 3 | |
| P921 | main subject | amphotericin B | Q412223 |
| P304 | page(s) | 203-206 | |
| P577 | publication date | 2003-03-01 | |
| P1433 | published in | Diagnostic Microbiology and Infectious Disease | Q15763479 |
| P1476 | title | Minimum fungicidal concentrations of amphotericin B for bloodstream Candida species | |
| P478 | volume | 45 |
| Q42107963 | Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing |
| Q42150481 | Activity of TDT 067 (terbinafine in Transfersome) against agents of onychomycosis, as determined by minimum inhibitory and fungicidal concentrations |
| Q33451098 | Activity of micafungin against Candida biofilms |
| Q35098733 | Anti-Candida activity of Quercus infectoria gall extracts against Candida species |
| Q33798546 | Anti-Candida activity of fluoxetine alone and combined with fluconazole: a synergistic action against fluconazole-resistant strains |
| Q47212233 | Anti-biofilm activity of low-molecular weight chitosan hydrogel against Candida species |
| Q42730616 | Anticandidal efficacy of cinnamon oil against planktonic and biofilm cultures of Candida parapsilosis and Candida orthopsilosis. |
| Q92738974 | Antifungal activity of silver nanoparticles in combination with ketoconazole against Malassezia furfur |
| Q36111677 | Antifungal chemotherapeutics |
| Q94460548 | Antimicrobial potential, phytochemical profile, cytotoxic and genotoxic screening of Sedum praealtum A. DC. (balsam) |
| Q60193426 | Association ofThymbra capitataessential oil and chitosan (TCCH hydrogel): a putative therapeutic tool for the treatment of vulvovaginal candidosis |
| Q37450019 | Candida parapsilosis and Candida guillermondii: emerging pathogens in nail candidiasis |
| Q41849134 | Caspofungin susceptibility testing of Candida inconspicua: correlation of different methods with the minimal fungicidal concentration |
| Q84752665 | Comparison of antifungal activities of gentian violet and povidone-iodine against clinical isolates of Candida species and other yeasts: a framework to establish topical disinfectant activities |
| Q40668521 | Comparison of the fungicidal activities of caspofungin and amphotericin B against Candida glabrata |
| Q35745822 | Determination of fungicidal activities against yeasts and molds: lessons learned from bactericidal testing and the need for standardization. |
| Q57348722 | Enhanced therapeutic efficacy of lipophilic amphotericin B against Candida albicans with amphiphilic poly(N-isopropylacrylamide) nanogels |
| Q40458611 | Epidemiology and antifungal susceptibility of Candida species isolated from blood: results of a 2-year multicentre study in Spain. |
| Q55510215 | Evaluation of a novel oxiconazole nitrate formulation: The thermosensitive gel. |
| Q52611998 | Fungicidal potency and mechanisms of θ-defensins against multi-drug resistant Candida species. |
| Q42110115 | Head-to-head comparison of inhibitory and fungicidal activities of fluconazole, itraconazole, voriconazole, posaconazole, and isavuconazole against clinical isolates of Trichosporon asahii |
| Q64948539 | Hydrogel of ketoconazole and PAMAM dendrimers: formulation and antifungal activity. |
| Q50353513 | Identification of Candida parapsilosis Sensu Lato in Pediatric Patients and Antifungal Susceptibility Testing. |
| Q56988745 | In vitro Assessment of Gentian Violet Anti-CandidaActivity |
| Q42111638 | In vitro activities of echinocandins against Candida krusei determined by three methods: MIC and minimal fungicidal concentration measurements and time-kill studies. |
| Q34083917 | In vitro activities of natural products against oral Candida isolates from denture wearers. |
| Q46250989 | In vitro activity of Spirulina platensis water extract against different Candida species isolated from vulvo-vaginal candidiasis cases. |
| Q43868191 | In vitro activity of amphotericin B and anidulafungin against Candida spp. biofilms |
| Q35997689 | In vitro anti-Candida activity of lidocaine and nitroglycerin: alone and combined |
| Q41564148 | In vitro antifungal activity and in vivo antibiofilm activity of cerium nitrate against Candida species |
| Q33736959 | In vitro antifungal activity of hydroxychavicol isolated from Piper betle L. |
| Q37124023 | In vitro antifungal activity of naftifine hydrochloride against dermatophytes |
| Q41581033 | In vitro inhibitory activity of terpenic derivatives against clinical and environmental strains of the Sporothrix schenkii complex. |
| Q46915149 | In vitro inhibitory effect of miltefosine against strains of Histoplasma capsulatum var. capsulatum and Sporothrix spp. |
| Q38547201 | In vitro susceptibility testing of amphotericin B for Cryptococcus neoformans variety grubii AFLP1/VNI and Cryptococcus gattii AFLP6/VGII by CLSI and flow cytometry |
| Q46263004 | Increasing the Fungicidal Action of Amphotericin B by Inhibiting the Nitric Oxide-Dependent Tolerance Pathway. |
| Q40659444 | Investigation of the antifungal activity of carvacrol against strains of Cryptococcus neoformans |
| Q42112398 | Killing kinetics of caspofungin, micafungin, and amphotericin B against Candida guilliermondii. |
| Q55511181 | Methodologies for in vitro and in vivo evaluation of efficacy of antifungal and antibiofilm agents and surface coatings against fungal biofilms. |
| Q49240555 | Methods for in vitro evaluating antimicrobial activity: A review |
| Q53128080 | Mucoadhesive in situ gel formulation for vaginal delivery of clotrimazole: formulation, preparation, and in vitro/in vivo evaluation. |
| Q40968227 | Patterns of amphotericin B killing kinetics against seven Candida species. |
| Q35933900 | Pharmacological assessment of the medicinal potential of Acacia mearnsii De Wild.: antimicrobial and toxicity activities |
| Q41878915 | Potent synergistic effect of doxycycline with fluconazole against Candida albicans is mediated by interference with iron homeostasis |
| Q51166410 | Prevalence and antifungal susceptibility of yeasts obtained from the oral cavity of elderly individuals. |
| Q33315163 | Propofol lipidic infusion promotes resistance to antifungals by reducing drug input into the fungal cell |
| Q34422986 | Relevant and selective activity of Pancratium illyricum L. against Candida albicans clinical isolates: a combined effect on yeast growth and virulence |
| Q91292102 | Rhesus Theta Defensin 1 Promotes Long Term Survival in Systemic Candidiasis by Host Directed Mechanisms |
| Q41888330 | Spondylodiscitis caused by Candida krusei: case report and susceptibility patterns. |
| Q58100719 | Spontaneous mutational frequency and mutation rates vary by echinocandin agent against |
| Q37159301 | Susceptibility testing of Candida albicans isolated from oropharyngeal mucosa of HIV(+) patients to fluconazole, amphotericin B and Caspofungin. killing kinetics of caspofungin and amphotericin B against fluconazole resistant and susceptible isolate |
| Q41247322 | Synergistic fungicidal activity of the lipopeptide bacillomycin D with amphotericin B against pathogenic Candida species. |
| Q33719218 | Synthesis, characterization, and in vitro activity against Candida spp. of fluconazole encapsulated on cationic and conventional nanoparticles of poly(lactic-co-glycolic acid) |
| Q38949297 | The Emerging Pathogen Candida auris: Growth Phenotype, Virulence Factors, Activity of Antifungals, and Effect of SCY-078, a Novel Glucan Synthesis Inhibitor, on Growth Morphology and Biofilm Formation. |
| Q37557695 | Trends in antifungal susceptibility testing using CLSI reference and commercial methods |
Search more.